Skip to main content
Top
Published in: Clinical Rheumatology 4/2012

01-04-2012 | Original Article

Assessment of fatigue and its relationships with disease-related parameters in patients with Systemic sclerosis

Authors: Yousra Ibn Yacoub, Bouchra Amine, Rachida Bensabbah, Najia Hajjaj-Hassouni

Published in: Clinical Rheumatology | Issue 4/2012

Login to get access

Abstract

We aimed to assess the prevalence and severity of fatigue in Moroccan patients with systemic sclerosis (SSc) and its relationship with disease-related parameters of activity and severity and quality of life (QoL). Patients with SSc according to the American College of Rheumatology criteria (diffuse disease) and/or the LeRoy and Medsger criteria (limited disease) for SSc were recruited. The multidimensional assessment of fatigue (MAF), a self-administered questionnaire developed to measure five dimensions of fatigue with a total score ranged from 0 (no fatigue) to 50 (severe fatigue), was used to assess fatigue. The activity of disease was assessed by evaluating the severity of skin involvement, vascular manifestations, pulmonary involvement, joint and/or muscle involvement, and the erythrocyte sedimentation rate. Functional disability was assessed by using the scleroderma health assessment questionnaire. QoL was assessed using the SF-36 generic instrument. Sixty-four patients (91% women) were included. The mean age of patients was 49.5 ± 12.4 years. Fifty-nine patients (92.1%) had diffuse SSc and 5 (7.8%) had limited disease. Among our patients, 89% experienced severe fatigue with a VAS fatigue ≥50 mm. The mean total score of the MAF was 28 ± 8.6 (10–44.8) and all domains of fatigue were affected. In univariate and multivariate analysis, fatigue was correlated with severe joint involvement, pain intensity, low vital capacity, high level of ESR, and with functional disability (for all p ≤ 0.01). There were statistically significant correlations between fatigue and the deterioration of all domains of SF-36. Fatigue is a disabling symptom in our SSc patients and is associated with poor QoL. Pain, joint involvement, functional impairment, and pulmonary involvement seem to be the most important factors that predict severe fatigue. Large studies are necessary in order to confirm those findings.
Literature
1.
go back to reference Rannou F, Poiraudeau S, Berezné A, Baubet T, Le-Guern V, Cabane J, Guillevin L, Revel M, Fermanian J, Mouthon L (2007) Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 57(1):94–102PubMedCrossRef Rannou F, Poiraudeau S, Berezné A, Baubet T, Le-Guern V, Cabane J, Guillevin L, Revel M, Fermanian J, Mouthon L (2007) Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 57(1):94–102PubMedCrossRef
2.
go back to reference Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE, Scleroderma Lung Study Group (2007) Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 66(12):1641–1647PubMedCrossRef Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE, Scleroderma Lung Study Group (2007) Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 66(12):1641–1647PubMedCrossRef
3.
go back to reference Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, Canadian Scleroderma Research Group (2009) Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 61(8):1112–1120PubMedCrossRef Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, Canadian Scleroderma Research Group (2009) Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 61(8):1112–1120PubMedCrossRef
4.
go back to reference Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA (2009) Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatol (Oxford) 48(2):165–169CrossRef Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA (2009) Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatol (Oxford) 48(2):165–169CrossRef
5.
go back to reference Danieli E, Airò P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, Franceschini F, Cattaneo R (2005) Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 24(1):48–54PubMedCrossRef Danieli E, Airò P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, Franceschini F, Cattaneo R (2005) Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 24(1):48–54PubMedCrossRef
6.
go back to reference Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, Ilie D, Rambeloarisoa J, Marjanovic Z, Cabane J, Sereni D, Pouchot J, Farge D (2006) Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatol (Oxford) 45(10):1298–1302CrossRef Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, Ilie D, Rambeloarisoa J, Marjanovic Z, Cabane J, Sereni D, Pouchot J, Farge D (2006) Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatol (Oxford) 45(10):1298–1302CrossRef
7.
go back to reference Sandqvist G, Scheja A, Hesselstrand R (2010) Pain, fatigue and hand function closely correlated to work ability and employment status in systemic sclerosis. Rheumatol (Oxford) 49(9):1739–1746CrossRef Sandqvist G, Scheja A, Hesselstrand R (2010) Pain, fatigue and hand function closely correlated to work ability and employment status in systemic sclerosis. Rheumatol (Oxford) 49(9):1739–1746CrossRef
8.
9.
go back to reference Masi AT, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Masi AT, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
10.
go back to reference LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed
11.
go back to reference Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W et al (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:42–46 Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W et al (2003) Assessment of disease severity and prognosis. Clin Exp Rheumatol 21:42–46
12.
go back to reference Minier T, Nagy Z, Bálint Z, Farkas H, Radics J, Kumánovics G, Czömpöly T, Simon D, Varjú C, Németh P, Czirják L (2010) Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatol 49(6):1133–1145CrossRef Minier T, Nagy Z, Bálint Z, Farkas H, Radics J, Kumánovics G, Czömpöly T, Simon D, Varjú C, Németh P, Czirják L (2010) Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatol 49(6):1133–1145CrossRef
13.
go back to reference Georges C, Chassany C, Mouthon L, Tiev K, Toledano C, Meyer O et al (2005) Validation of French version of the scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 24:3–10PubMedCrossRef Georges C, Chassany C, Mouthon L, Tiev K, Toledano C, Meyer O et al (2005) Validation of French version of the scleroderma Health Assessment Questionnaire (SSc HAQ). Clin Rheumatol 24:3–10PubMedCrossRef
14.
go back to reference Khoudri I, Ali Zeggwagh A, Abidi K, Madani N, Abouqal R (2007) Measurement properties of the short form 36 and health-related quality of life after intensive care in Morocco. Acta Anaesthesiol Scand 51(2):189–197PubMedCrossRef Khoudri I, Ali Zeggwagh A, Abidi K, Madani N, Abouqal R (2007) Measurement properties of the short form 36 and health-related quality of life after intensive care in Morocco. Acta Anaesthesiol Scand 51(2):189–197PubMedCrossRef
15.
go back to reference Richards HL, Herrick AL, Griffin K, Gwilliam PD, Loukes J, Fortune DG (2003) Systemic sclerosis: patients’ perceptions of their condition. Arthritis Rheum 49:689–696PubMedCrossRef Richards HL, Herrick AL, Griffin K, Gwilliam PD, Loukes J, Fortune DG (2003) Systemic sclerosis: patients’ perceptions of their condition. Arthritis Rheum 49:689–696PubMedCrossRef
16.
go back to reference Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M (2007) Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 34:1718–1726PubMed Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M (2007) Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 34:1718–1726PubMed
17.
go back to reference Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA (2004) Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 51(4):578–585PubMedCrossRef Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA (2004) Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 51(4):578–585PubMedCrossRef
18.
go back to reference Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL (2006) Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatol (Oxford) 45(7):885–889CrossRef Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL (2006) Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatol (Oxford) 45(7):885–889CrossRef
19.
go back to reference Hyphantis TN, Tsifetaki N, Pappa C, Voulgari PV, Siafaka V, Bai M, Alamanos Y, Drosos AA, Mavreas V (2007) Clinical features and personality traits associated with psychological distress in systemic sclerosis patients. J Psychosom Res 62(1):47–56PubMedCrossRef Hyphantis TN, Tsifetaki N, Pappa C, Voulgari PV, Siafaka V, Bai M, Alamanos Y, Drosos AA, Mavreas V (2007) Clinical features and personality traits associated with psychological distress in systemic sclerosis patients. J Psychosom Res 62(1):47–56PubMedCrossRef
20.
go back to reference Hudson M, Thombs BD, Steele R, Watterson R, Taillefer S, Baron M, Canadian Scleroderma Research Group Investigators (2008) Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis Rheum 59(2):279–284PubMedCrossRef Hudson M, Thombs BD, Steele R, Watterson R, Taillefer S, Baron M, Canadian Scleroderma Research Group Investigators (2008) Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis Rheum 59(2):279–284PubMedCrossRef
Metadata
Title
Assessment of fatigue and its relationships with disease-related parameters in patients with Systemic sclerosis
Authors
Yousra Ibn Yacoub
Bouchra Amine
Rachida Bensabbah
Najia Hajjaj-Hassouni
Publication date
01-04-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1906-z

Other articles of this Issue 4/2012

Clinical Rheumatology 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine